(2) *LILLY'S SOLANEZUMAB DIDN'T MEET PRIMARY ENDPOINT IN TRIAL

*LILLY'S SOLANEZUMAB DIDN'T MEET PRIMARY ENDPOINT IN TRIAL

Alerts: HALISTER, HALISTER1
Source: BN (Bloomberg News)

Tickers
LLY US (Eli Lilly & Co)

People
David Ricks (Eli Lilly & Co)
Jan Lundberg (Eli Lilly & Co)
John Lechleiter (Eli Lilly & Co)
Philip Johnson (Eli Lilly & Co)

To de-activate the "HALISTER" alert, click here
To modify this alert, click here

To de-activate the "HALISTER1" alert, click here
To modify this alert, click here

UUID: 7947283